Literature DB >> 21897689

Mania associated with complicated hereditary spastic paraparesis.

Raghavendra B Nayak1, Govind S Bhogale, Nanasaheb M Patil, Aditya A Pandurangi.   

Abstract

Hereditary spastic paraparesis (HSP) is an inherited group of neurological disorders with progressive lower limb spasticity. HSP can be clinically grouped into pure and complicated forms. Pure HSP is one without any associated neurological/psychiatric comorbidity. Depression is the most common psychiatric comorbidity. Presence of mania or bipolar affective illness with HSP is a rare phenomenon. We report a case of a 17-year-old boy who presented with classical features of HSP with complaints of excessive happiness, irritability, increased self-esteem and decreased sleep since 1 month. The patient also had complex partial seizure ever since he had features of HSP. The patient's father and younger sister suffer from pure HSP. The patient was diagnosed to have first episode mania with complicated HSP. The details of treatment and possible neurobiology are discussed in this case report.

Entities:  

Keywords:  Complicated hereditary spastic paraparesis; hereditary spastic paraparesis; mania

Year:  2011        PMID: 21897689      PMCID: PMC3159362          DOI: 10.4103/0976-3147.83592

Source DB:  PubMed          Journal:  J Neurosci Rural Pract        ISSN: 0976-3155


Introduction

Hereditary spastic paraparesis (HSP) or Strümpell–Lorrain syndrome is an inherited group of neurological disorders with progressive lower limb spasticity. HSP is classified into pure/uncomplicated and complicated/complex forms. HSP is transmitted through an autosomal-dominant (AD), autosomal-recessive (AR) or X-linked (XL) manner. An AD transmission accounts for 70–80% of all HSP.[1] It affects all the age groups, and the prevalence of HSP ranges from 2.0 to 9.6/100,000 depending on different diagnostic criteria used and populations studied.[2] The cardinal abnormalities of patients with HSP include spasticity, hyperreflexia, urinary bladder disturbance (hypertonic bladder) and extensor plantar responses with weakness of a pyramidal distribution in the lower limbs. We report a case of a 17-year-old boy who presented with HSP and mania. The possible association of HSP with bipolar disorder has not been frequently addressed in the medical literature.

Case Report

A 17-year-old boy reported to the Department of Psychiatry with complaints of excessive happiness, irritability, increased self-esteem and decreased sleep since 1 month. The patient was known case of HSP with epilepsy since 7 years. He was born of a nonconsanguinous marriage. Details of family are mentioned in the family genogram [Figure 1]. The patient had episodes of staring, twitching around the mouth, grimacing followed by loss of consciousness and fall followed by involuntary jerky movements of the extremities. His seizures and neurological illness had both started simultaneously. The patient was taking Tab carbamazepine 400 mg/day for the last 5 years. Seizure episodes decreased after starting carbamazepine from three to four episodes in a year to total absence of episodes in last 3 years. The patient's father and sister also have HSP without any diagnosable psychiatric or epileptic disorders. All the affected family members had onset of HSP around 12 years of age, which had progressed for 3–4 years and, later, the condition became static. The patient's mother had a history of paranoid schizophrenia; she had committed suicide 8 years ago.
Figure 1

Family genogram

Family genogram On general physical examination, the patient was moderately built and nourished, with normal vital parameters. He was conscious and well-oriented during examination. His neurological examination revealed that both his limbs were equally affected. There was increased muscle tone in the hamstring group and in the ankle region, positive patellar clonus and Babinski's sign, brisk deep tendon reflexes, wasting of distal muscle groups and spastic gait. There were no cranial nerve deficits, cerebellar signs and signs of meningeal irritation. On mental status examination, he was well kempt, had increased psychomotor activity, pressure of speech, irritability, increased self-esteem and delusion of grandiosity. When baseline Young's Mania Rating Scale (YMRS) was applied, the score was 26, and his baseline hematological and biochemical investigations were within normal limits. Computed tomography imaging did not reveal any abnormalities. Diagnosis of the first episode of mania with psychotic symptoms was made using ICD-10 DCR criteria.[3] The patient was independently interviewed by two competent psychiatrists to rule out any other psychiatric disorders, but screening instruments like SCID or MINI were not used. The patient was given Tab Sodium Valproate 500 mg bid/day and Tab Olanzapine 15 mg/day. Valproate was cross-tapered with carbamazepine over a period of 2 weeks. Considering the poor response during the first 2 weeks with Olanzapine and a similar observation by the family members, the treating team decided to change Olanzapine to Tab Trifluoperazine 10 mg bid/day and Tab Trihexyphenidyl 2 mg bid/day. The patient showed good improvement to the change of these medications and his YMRS score decreased to 10 after 10 days. Then, the patient was discharged and was asked to come for a follow-up. Antipsychotic medications were stopped after 3 months and only Valproate was continued. The patient is regularly followed-up for 6 months and his symptoms have shown remission. There are no recurrences of seizure episodes.

Discussion

On evaluation, the patient had severe mania with a YMRS score of 26. The presence of severe manic symptoms warranted the use of a mood stabilizer Valproate in the first episode itself.[4] Tab Valproate was cross-tapered along with tab carbamazepine because, clinically, we use Valproate more commonly as compared with carbamazepine. The risk of changing carbamazepine was discussed with the family members as carbamazepine was the better choice for complex partial seizures.[5] Ideally, in our case, Olanzapine should have been continued for 4-6 weeks as per the guidelines, but due to inadequate response and request by the family members, the treating team decided to change Olanzapine to Trifluoperazine. In 1981, Harding et al.[6] detailed the clinical evaluation of 22 families and suggested criteria for classifying HSP into pure and complicated forms. Pure HSP is without any associated neurological/psychiatric comorbidity. Complicated hereditary spastic paraparesis has been associated with many conditions, including optic atrophy, retinopathy, extrapyramidal disease, amyotrophy, dementia, ataxia, mental retardation, deafness, icthyosis, peripheral neuropathy, epilepsy and psychiatric disorders.[2] The major neuropathological feature of pure HSP is axonal degeneration, which is maximal in the terminal portions of the longest descending (corticospinal tracts) and ascending (dorsal column pathways) tracts within the spinal cord. The genetic profile of HSP reveals 32 HSP loci and 11 disease-related genes. Of the loci, 13 are responsible for AD HSP and 4 for XL-HSP. A group of the proteins they encode localize to the endosomal membrane traffic compartment, suggesting that the long axons of the corticospinal tract may be especially vulnerable to endosomal dysfunction and lead to physical symptoms.[7] However, psychiatric manifestations are rare but mood disorders, organic personality changes, dementia, psychosis and mental retardation may be associated with this condition. Depression is the most common psychiatric comorbidity. A study of 48 patients with HSP revealed that 58% of the patients suffer from depression. Most patients had mild to moderate depression, and only one had a severe depressive episode.[8] Bipolar affective disorder is a rare association with HSP. There are only two reported cases in the literature.[910] A study in the Irish population reports that patients with HSP are at a higher risk of developing psychosis.[11] The neurobiology of HSP with psychiatric manifestations is not clear. Psychosis is common in families with Kjellin's syndrome and SPG4-HSP.[11] In the above Irish study, patients had ventricular enlargement and mild generalized atrophy on cranial imaging.[11] A clinicopathological study of a family in Japan showed that all the patients had hypoperfusion in the frontal lobes and thalami on SPECT, and neuropathologic findings revealed thin corpus callosum and degeneration in the thalamic dorsomedial nuclei as well as degeneration of the corticospinal tracts.[12] Reports suggest that white matter abnormalities in the brain are commonly noted in patients with bipolar affective disorder. The tracts connecting the frontal lobe and subcortical structures are implicated in the neurobiology of bipolar affective disorder.[13] White matter abnormalities could be one common factor between HSP and mania. Sometimes, mania and epilepsy together can occur and are believed to be having a common underlying neurobiology, like kindling paradigm and changes in second-messenger systems.[14] But, the prevalence of true manic depressive illness in epilepsy has been demonstrated to be in line with that reported in the general population (about 2%) and, therefore, is difficult to consider the common underlying neurobiology.[15] The patient's mother had paranoid schizophrenia, which could be another factor for the above association, because affective disorders are reported in the same family who have schizophrenia spectrum disorders, but this is uncommon.

Conclusions

Mania is a coincidental occurrence that needs evaluation for association with HSP. However, there may be common underlying factors as suggested by this case. Thus, the diagnosed cases of HSP need detailed evaluation for psychiatric morbidity.
  13 in total

Review 1.  Hereditary spastic paraparesis: a review of new developments.

Authors:  C McDermott; K White; K Bushby; P Shaw
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

2.  The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland.

Authors:  P McMonagle; S Webb; M Hutchinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

3.  Hereditary spastic paraparesis and psychosis.

Authors:  P McMonagle; M Hutchinson; B Lawlor
Journal:  Eur J Neurol       Date:  2006-08       Impact factor: 6.089

4.  Hypomanic behaviour associated with familial spastic paraplegia.

Authors:  P H Jansen; A Keyser; B C Raes
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

Review 5.  Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.

Authors:  H S Akiskal; M L Bourgeois; J Angst; R Post; H Möller; R Hirschfeld
Journal:  J Affect Disord       Date:  2000-09       Impact factor: 4.839

6.  Hereditary spastic paraplegia, bipolar affective disorder and intellectual disability: a case report.

Authors:  Marie Whitty; Fionnuala Kelly; Louis Ramsay
Journal:  J Intellect Disabil       Date:  2008-03

Review 7.  A role for white matter abnormalities in the pathophysiology of bipolar disorder.

Authors:  Katie Mahon; Katherine E Burdick; Philip R Szeszko
Journal:  Neurosci Biobehav Rev       Date:  2009-11-06       Impact factor: 8.989

8.  Hereditary "pure" spastic paraplegia: a clinical and genetic study of 22 families.

Authors:  A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-10       Impact factor: 10.154

Review 9.  Bipolar disorder and epilepsy: a bidirectional relation? Neurobiological underpinnings, current hypotheses, and future research directions.

Authors:  Marianna Mazza; Marco Di Nicola; Giacomo Della Marca; Luigi Janiri; Pietro Bria; Salvatore Mazza
Journal:  Neuroscientist       Date:  2007-08       Impact factor: 7.519

10.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.